European Investment Fund and cancer research charity launch new £50m fund
This article was originally published in Scrip
Executive Summary
Cancer Research Technology (CRT), the corporate arm of the charity Cancer Research UK, and the European Investment Fund (EIF) have joined together to create a £50 million investment fund aimed at bridging the gap between cancer drug discovery and early clinical development in the UK.
You may also be interested in...
Tech Transfer Roundup: Novo Nordisk Foundation, Broad Institute Team On Genomic Drivers Of Disease
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.